Alkermes $ALKS posted Q3 EPS of -$0.09, missing the guidance by $0.03. Revenue was $182.24 million, a 19.4% growth Y-o-Y but missing the forecast by $4.15 million. For the quarter, VIVITROL Net Sales increased 47% Year-Over-Year to $55.8 Million. The company said that ARISTADA launch is progressing and revenues grew in-line with expectations.